1 hour every 3 weeks

SYLVANT is given as an intravenous (IV) infusion directly into the bloodstream.

An iMCD patient in a white hoodie is ready to fight back with Sylvant.

Getting your SYLVANT infusion

Before administering SYLVANT® (siltuximab), your doctor will perform blood tests to check that your body is ready to receive treatment. The tests are performed prior to every infusion for the first 12 months, and then every 3 dosing cycles thereafter.

What to expect

SYLVANT is an infusion treatment administered at a hospital, infusion center, or home by a trained healthcare professional.

Comfort icon

Make comfort a priority: wear loose-fitting clothing and layers in case you get too warm or too cold.

book help pass time Sylvant icon

Bring a book, laptop, tablet, or any other digital device to help pass the time.

infusion Sylvant icon

The infusion is given over 1 hour, every 3 weeks.

Exclamation icon

After your first infusion, try not to make any other commitments for the rest of the day, as you won’t know how your body will react to the infusion.

letter icon

Treatment with SYLVANT should be continued until disease progression.

When I received my iMCD diagnosis, I was relieved because I knew I was going to receive the proper treatment…and that made me hopeful for the future.

– Jessica, iMCD patient

Jessica, iMCD patient testimonial Sylvant

Home infusion

Before you can begin your home infusion, you must receive your first SYLVANT infusion at a clinic or hospital.

You still have the option to continue your treatment at a hospital, clinic, or infusion center. To enroll in home infusion, or for additional information, please contact your healthcare provider.

An iMCD patient sitting on a couch receives their Sylvant infusion at home
letter icon

Need more information?

Sign up to receive emails about iMCD, SYLVANT, lifestyle tips, patient stores, and more.

eye icon

Insights on iMCD

Are you an iMCD patient or caregiver?*
Have you been prescribed SYLVANT® (siltuximab) for the treatment of iMCD?*
By checking the box above, you agree to allow EUSA Pharma to collect the information provided and to be contacted by EUSA Pharma in the future regarding its IL-6 neutralizing products and related disease education. By submitting this form, you agree to allow EUSA Pharma to collect the information provided and to be contacted directly by a EUSA Pharma sales representative. Your information will not be used for any other purpose than for a representative to respond to your information request, or for us to send you other EUSA Pharma updates if you have registered to receive them. EUSA Pharma will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of EUSA Pharma. EUSA Pharma will only use your information in accordance with its Privacy Policy.
See More

SYLVANT® (siltuximab) for injection

APPROVED USE

SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection.

It is not known if SYLVANT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take SYLVANT if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT. See the Patient Information for SYLVANT for a complete list of ingredients.

SYLVANT® (siltuximab) for injection

APPROVED USE

SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman’s disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection.

It is not known if SYLVANT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take SYLVANT if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT. See the Patient Information for SYLVANT for a complete list of ingredients.

Tell your healthcare provider if you have an infection. You should not receive SYLVANT if you have a severe infection.

Tell your healthcare provider if you have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive a live vaccine during your treatment with SYLVANT.

Tell your healthcare provider if you are pregnant or plan to become pregnant. It is not known if SYLVANT will harm your unborn baby. You should not become pregnant while receiving treatment with SYLVANT. Females who are able to become pregnant should use effective birth control during treatment with SYLVANT and for 3 months after stopping treatment.

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if SYLVANT passes into your breast milk. You and your healthcare provider should decide if you will take SYLVANT or breastfeed. You should not do both.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of SYLVANT include rash, itching, upper respiratory tract infection, swelling, weight gain, and increased blood level of uric acid.

These are not all the possible side effects of SYLVANT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For more information, please see the full Prescribing Information.

R.A.R.E. Assistance R.A.R.E®
Assistance Patient Liaison Patient
Liaison